The abstract is read at the publisher; the summary is JClub's.
Prim-O-glucosylcimifugin (POG) suppresses M2 macrophage polarization in ovalbumin-induced allergic asthma in mice by downregulating the JAK2-STAT6-PPARγ axis.
- Why it matters: Allergic asthma is driven by immune inflammation linked to M2 macrophage polarization, but how POG modulates this pathway in AA was unclear.
- What they did: LC-MS profiling and network pharmacology identified POG as a key active ingredient from Saposhnikovia divaricata/Prunus mume, then OVA plus IL-4 models were used in mice and RAW264.7 cells with pathway readouts by flow cytometry, RT-qPCR, immunofluorescence, and Western blot.
- The result: POG reduced OVA-induced airway inflammation and lung histopathological damage and inhibited M2 polarization by lowering JAK2-STAT6-PPARγ factors, decreasing type II immune inflammatory marker release.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.